Literature DB >> 25740064

Mechanistic approach to the pathophysiology of target organ damage in hypertension from studies in a human model with characteristics opposite to hypertension: Bartter's and Gitelman's syndromes.

L A Calò1, G Maiolino2.   

Abstract

INTRODUCTION: Extensive studies using Bartter's/Gitelman's syndrome patients have provided insights into the angiotensin II (Ang II) signaling pathways involved in the regulation of vascular tone and cardiovascular-renal remodeling. The renin-angiotensin-aldosterone system is activated in these syndromes, however, patients do not develop hypertension and cardiovascular remodeling and clinically manifest conditions opposite to hypertension. The short- and the long-term signaling of Ang II remains an important matter of investigation to shed light on mechanisms responsible for the pathophysiology of hypertension and its long-term complications. The long-term signaling of Ang II is involved in the pathophysiology of cardiovascular-renal remodeling and inflammatory responses in which the balance between RhoA/Rho kinase pathway and NO system plays a crucial role. METHODS AND
RESULTS: In this brief review, the results of our studies in Bartter's and Gitelman's syndromes are reported on these processes.
CONCLUSIONS: The information obtained from these studies can clarify, confirm or be used to extend the biochemical mechanisms responsible for the pathophysiology of hypertension and its long-term complications and could offer further chances to identify additional potential significant targets of therapy.

Entities:  

Keywords:  Angiotensin II signaling; Bartter’s syndrome; Cardiovascular–renal remodeling; Gitelman’s syndrome; Hypertension; Nitric oxide; Rho kinase

Mesh:

Year:  2015        PMID: 25740064     DOI: 10.1007/s40618-015-0249-z

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  48 in total

Review 1.  Rho kinase and hypertension.

Authors:  Angela Wirth
Journal:  Biochim Biophys Acta       Date:  2010-05-09

2.  Rho kinase inhibition and vascular protection: support from studies in Bartter and Gitelman syndrome.

Authors:  Lorenzo A Calò; Elisa Pagnin; Paul A Davis; Michelangelo Sartori; Andrea Semplicini; Achille C Pessina
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-04       Impact factor: 8.311

3.  Hypoxia-induced upregulation of endothelial small G protein RhoA and Rho-kinase/ROCK2 inhibits eNOS expression.

Authors:  Hong Guo Jin; Hiroshi Yamashita; Yoshito Nagano; Hiromasa Fukuba; Masanori Hiji; Toshiho Ohtsuki; Tetsuya Takahashi; Tatsuo Kohriyama; Kozo Kaibuchi; Masayasu Matsumoto
Journal:  Neurosci Lett       Date:  2006-09-25       Impact factor: 3.046

4.  Endothelial progenitor cells relationships with clinical and biochemical factors in a human model of blunted angiotensin II signaling.

Authors:  Lorenzo A Calò; Monica Facco; Paul A Davis; Elisa Pagnin; Lucia Dal Maso; Massimo Puato; Paola Caielli; Carlo Agostini; Achille C Pessina
Journal:  Hypertens Res       Date:  2011-06-09       Impact factor: 3.872

Review 5.  Angiotensin II and vascular inflammation.

Authors:  Zhong Jian Cheng; Heikki Vapaatalo; Eero Mervaala
Journal:  Med Sci Monit       Date:  2005-05-25

Review 6.  Is angiotensin-II an endogenous pro-inflammatory molecule?

Authors:  Undurti N Das
Journal:  Med Sci Monit       Date:  2005-04-28

7.  High angiotensin II state without cardiac remodeling (Bartter's and Gitelman's syndromes): are angiotensin II type 2 receptors involved?

Authors:  L A Calò; R Montisci; R Scognamiglio; P A Davis; E Pagnin; S Schiavo; P Mormino; A Semplicini; P Palatini; A D'Angelo; A C Pessina
Journal:  J Endocrinol Invest       Date:  2009-07-14       Impact factor: 4.256

8.  Oxidative stress-related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling.

Authors:  Lorenzo A Calò; Elisa Pagnin; Paul A Davis; Michelangelo Sartori; Andrea Semplicini
Journal:  Nephrol Dial Transplant       Date:  2003-08       Impact factor: 5.992

9.  Linking inflammation and hypertension in humans: studies in Bartter's/Gitelman's syndrome patients.

Authors:  L A Caló; P A Davis; E Pagnin; S Schiavo; A Semplicini; A C Pessina
Journal:  J Hum Hypertens       Date:  2007-11-29       Impact factor: 3.012

10.  Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's syndrome. A role in the control of vascular tone and implication for hypertension.

Authors:  Lorenzo A Calò; Elisa Pagnin; Paul A Davis; Michelangelo Sartori; Giulio Ceolotto; Achille C Pessina; Andrea Semplicini
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

View more
  4 in total

Review 1.  Pharmacological interventions into the renin-angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: effects beyond blood pressure lowering.

Authors:  Rainer Düsing
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-04-27

2.  Oxidative stress and the altered reaction to it in Fabry disease: A possible target for cardiovascular-renal remodeling?

Authors:  Verdiana Ravarotto; Gianni Carraro; Elisa Pagnin; Giovanni Bertoldi; Francesca Simioni; Giuseppe Maiolino; Matteo Martinato; Linda Landini; Paul A Davis; Lorenzo A Calò
Journal:  PLoS One       Date:  2018-09-27       Impact factor: 3.240

3.  Rho Kinase Activity, Connexin 40, and Atrial Fibrillation: Mechanistic Insights from End-Stage Renal Disease on Dialysis Patients.

Authors:  Lorenzo A Calò; Verdiana Ravarotto; Giovanni Bertoldi; Elisa Pagnin; Barbara Rossi; Matteo Rigato; Paul A Davis; Riccardo Proietti
Journal:  J Clin Med       Date:  2020-01-07       Impact factor: 4.241

4.  Assessing the Relationship of Angiotensin II Type 1 Receptors with Erythropoietin in a Human Model of Endogenous Angiotensin II Type 1 Receptor Antagonism.

Authors:  Lorenzo A Calò; Paul A Davis; Giuseppe Maiolino; Elisa Pagnin; Verdiana Ravarotto; Elena Naso; Gianni Carraro; Agostino Naso
Journal:  Cardiorenal Med       Date:  2015-09-17       Impact factor: 2.041

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.